- Home
- TERN vs OCUL Comparison
TERN vs OCUL Comparison
Compare TERN & OCUL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TERN | OCUL |
|---|---|---|
| Founded | 2017 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.4B |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | TERN | OCUL |
|---|---|---|
| Price | $39.59 | $12.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 10 |
| Target Price | ★ $48.60 | $22.56 |
| AVG Volume (30 Days) | ★ 4.9M | 3.8M |
| Earning Date | 11-10-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $55,783,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $14.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.87 | $5.79 |
| 52 Week High | $48.26 | $16.44 |
Technical Indicators
Market Signals| Indicator | TERN | OCUL |
|---|---|---|
| Relative Strength Index (RSI) | 65.97 | 49.08 |
| Support Level | $25.67 | $11.15 |
| Resistance Level | $45.17 | $14.64 |
| Average True Range (ATR) | 3.71 | 0.86 |
| MACD | 0.08 | -0.05 |
| Stochastic Oscillator | 63.41 | 34.66 |
Price Performance
Historical ComparisonAbout TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.
About OCUL Ocular Therapeutix Inc.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.